Come January 2005, the Indian pharmaceutical industry will face a new product patent regime. With the world market throwing up huge opportunities like off-patent drugs worth $50 billion (Rs 240,000 crore) by 2007 and a visible move by multinational drug majors towards outsourcing research and development as well as manufacturing activities out of India, domestic drug firms are strategically poisitioning themselves and gearing up to make the most of it.
P A Modi, chairman and managing director of Unichem Laboratories, speaks about the company
